PetIQ Inc (NASDAQ:PETQ) Receives $41.14 Average Price Target from Brokerages

Share on StockTwits

Shares of PetIQ Inc (NASDAQ:PETQ) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $41.14.

Several equities analysts have recently weighed in on PETQ shares. ValuEngine cut PetIQ from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded PetIQ from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Friday, August 9th. Guggenheim started coverage on PetIQ in a research report on Thursday, May 23rd. They issued a “buy” rating and a $35.00 price target for the company. Finally, BidaskClub cut PetIQ from a “buy” rating to a “hold” rating in a research report on Thursday.

Shares of PETQ traded down $1.09 during mid-day trading on Friday, hitting $31.07. The stock had a trading volume of 11,740 shares, compared to its average volume of 491,942. The company has a market capitalization of $906.91 million, a price-to-earnings ratio of 24.98, a P/E/G ratio of 1.26 and a beta of 2.06. The stock’s fifty day moving average price is $34.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.51 and a current ratio of 2.89. PetIQ has a 52 week low of $21.29 and a 52 week high of $43.93.

PetIQ (NASDAQ:PETQ) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.35. The company had revenue of $220.60 million during the quarter, compared to analysts’ expectations of $193.89 million. PetIQ had a return on equity of 10.54% and a net margin of 0.68%. The firm’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 earnings per share. As a group, research analysts predict that PetIQ will post 1.07 earnings per share for the current year.

In other news, insider Will Santana sold 20,000 shares of PetIQ stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $28.16, for a total value of $563,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 110,291 shares of company stock valued at $3,436,491. 23.79% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Waddell & Reed Financial Inc. raised its position in PetIQ by 11.4% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,780,931 shares of the company’s stock valued at $58,699,000 after purchasing an additional 182,205 shares during the last quarter. Nuveen Asset Management LLC bought a new position in PetIQ during the 2nd quarter valued at approximately $2,356,000. UBS Asset Management Americas Inc. bought a new position in PetIQ during the 2nd quarter valued at approximately $313,000. AQR Capital Management LLC raised its position in PetIQ by 4.0% during the 2nd quarter. AQR Capital Management LLC now owns 9,620 shares of the company’s stock valued at $317,000 after purchasing an additional 367 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its position in PetIQ by 1,205.8% during the 2nd quarter. Marshall Wace North America L.P. now owns 57,428 shares of the company’s stock valued at $1,893,000 after purchasing an additional 53,030 shares during the last quarter. Institutional investors and hedge funds own 89.80% of the company’s stock.

About PetIQ

PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.

See Also: Debt-To-Equity Ratio

Analyst Recommendations for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Peabody Energy Co.  to Issue Dividend Increase – $0.15 Per Share
Peabody Energy Co. to Issue Dividend Increase – $0.15 Per Share
Dillard’s  PT Lowered to $37.00 at JPMorgan Chase & Co.
Dillard’s PT Lowered to $37.00 at JPMorgan Chase & Co.
Morgan Stanley Cuts CMS Energy  Price Target to $59.00
Morgan Stanley Cuts CMS Energy Price Target to $59.00
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR  to Sell
Zacks Investment Research Lowers RANDSTAD HLDG N/ADR to Sell
MediciNova  Cut to Strong Sell at BidaskClub
MediciNova Cut to Strong Sell at BidaskClub
Westinghouse Air Brake Technologies  Downgraded by ValuEngine
Westinghouse Air Brake Technologies Downgraded by ValuEngine


 
© 2006-2019 Zolmax.